Comparison

TRAF2 Antibody (C-term) Blocking Peptide

Item no. ABC-BP7825b
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Lyophilized
Specific against other
Citations Merluzzi,S., Mol. Immunol. 45 (1), 76-86 (2008)Mainou,B.A., J. Virol. 81 (18), 9680-9692 (2007)Morrison,B.H., J. Biol. Chem. 282 (21), 15349-15356 (2007)
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias TNF receptor-associated factor 2,632-,E3 ubiquitin-protein ligase TRAF2,Tumor necrosis factor type 2 receptor-associated protein 3,TRAF2,TRAP3
Similar products TRAF2, TRAP3, TNF receptor-associated factor 2, E3 ubiquitin-protein ligase TRAF2, Tumor necrosis factor type 2 receptor-associated protein 3, 632-
Available
Manufacturer - Category
Peptides; Blocking Peptides
Manufacturer - Targets
The synthetic peptide sequence used to generate the antibody AP7825b was selected from the C-term region of human TRAF2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Bio Background
TRAF2 is a member of the TNF receptor associated factor (TRAF) protein family. TRAF proteins associate with, and mediate the signal transduction from members of the TNF receptor superfamily. This protein directly interacts with TNF receptors, and forms a heterodimeric complex with TRAF1. This protein is required for TNF-alpha-mediated activation of MAPK8/JNK and NF-kappaB. The protein complex formed by this protein and TRAF1 interacts with the inhibitor-of-apoptosis proteins (IAPs), and functions as a mediator of the anti-apoptotic signals from TNF receptors. The interaction of this protein with TRADD, a TNF receptor associated apoptotic signal transducer, ensures the recruitment of IAPs for the direct inhibition of caspase activation. BIRC2/c-IAP1, an apoptosis inhibitor possessing ubiquitin ligase activity, can unbiquitinate and induce the degradation of this protein, and thus potentiate TNF-induced apoptosis.
Gene Name
TRAF2 {ECO:0000303|PubMed:28489822, ECO:0000312|HGNC:HGNC:12032}
Subtitle
Synthetic peptide
Formulation
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close